Assembly biosciences and arbutus biopharma announce clinical collaboration agreement

Assembly biosciences and arbutus biopharma announce clinical collaboration agreement to evaluate the combination of core inhibitor abi-h0731 with rnai therapeutic ab-729 in patients with chronic hepatitis b virus infection.arbutus biopharma - phase 2 clinical trial will explore safety, pharmacokinetics, and antiviral activity of triple combination of hbv core inhibitors.arbutus biopharma corp - clinical trial is projected to initiate in first half of 2021.
ABUS Ratings Summary
ABUS Quant Ranking